

In the Claims

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Original) A pharmaceutical composition comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin.
2. (Currently Amended) ~~A The composition according to of claim 1 wherein the first specific binding agent comprises a large binding fragment of an antibody.~~
3. (Currently Amended) ~~A The composition according to of claim 2 wherein the large binding fragment of an antibody is a an F(ab')₂ or F(ab)₂ fragment.~~
4. (Currently Amended) ~~A The composition according to of claim 1 wherein the first specific binding agent is an antibody which is IgG or IgT.~~
5. (Currently Amended) ~~A The composition according to of claim 4 wherein the antibody is humanised.~~
6. (Currently Amended) ~~A The composition according to any one of the preceding claims of claim 1 wherein the second specific binding agent comprises an Fab, Fab', a single chain (sc) antibody or an FV, VH or VK fragment.~~
7. (Currently Amended) ~~A The composition according to of claim 6 wherein the second specific binding agent comprises an Fab or Fab' fragment.~~

Filed: 05 December 2005

PRELIMINARY AMENDMENT

8. (Currently Amended) ~~A The composition according to any one of the preceding claims of claim 1~~ wherein the first and/or second binding agents are derived from polyclonal antibodies.

9. (Currently Amended) ~~A The composition according to any one of claims 1 to 7 of claim 1~~ wherein the first and/or second binding agents are derived from monoclonal antibodies.

10. (Currently Amended) ~~A The composition according to any one of the preceding claims of claim 1~~ wherein at least one of the first or second specific binding agents includes a section corresponding to part of the Fc region of an antibody.

11. (Currently Amended) ~~A The composition according to any one of the preceding claims of claim 1~~ wherein the toxin is a Botulinum toxin.

12. (Currently Amended) ~~A The composition according to of claim 11~~ wherein the first and second specific binding agents bind at least one of type A, B, C, D, E, F or G botulinum toxin.

13. (Currently Amended) ~~A The composition according to of claim 12~~ wherein the composition comprises sets of first and second specific binding agents each set of specific binding agents binding a different one of botulinum toxins A, B, C, D, E, F or G.

14. (Currently Amended) ~~A The composition according to any one of the preceding claims of claim 1~~ wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 90:10 to 10:90.

15. (Currently Amended) ~~A The composition according to of claim 14~~ wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 70:30 to 30:70.

Filed: 05 December 2005

PRELIMINARY AMENDMENT

16. (Currently Amended) ~~A The composition according to of claim 15 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 60:40 to 40:60.~~

17. (Currently Amended) ~~A The composition according to any one of the preceding claims of claim 1 which further comprises a pharmaceutically acceptable carrier or excipient.~~

18. (Currently Amended) ~~A The composition according to any one of the preceding claims of claim 1 which is suitable for oral, parenteral, or intranasal administration, or for administration by inhalation or insufflation.~~

19. (Currently Amended) ~~A method for treating the adverse effects of a toxin on a mammal comprising administering to a mammal in thereof a composition comprising combination of (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin ,for use in the treatment of the effects of the toxin.~~

20. (Cancelled)

21. (Currently Amended) ~~A method of preventing the effects of a toxin on a mammal such as a human, said method comprising administering to a mammal in need thereof, a composition according to any one of claims 1 to 18 comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin.~~

22. (Cancelled)